Published in Antimicrob Agents Chemother on August 01, 2006
Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog (2008) 2.80
Animal models of mucosal Candida infection. FEMS Microbiol Lett (2008) 1.33
Hosting infection: experimental models to assay Candida virulence. Int J Microbiol (2011) 1.14
New insights into innate immune control of systemic candidiasis. Med Mycol (2014) 1.05
Murine models of Candida gastrointestinal colonization and dissemination. Eukaryot Cell (2013) 0.97
Innocent until proven guilty: mechanisms and roles of Streptococcus-Candida interactions in oral health and disease. Mol Oral Microbiol (2014) 0.95
A novel immunocompetent murine model for Candida albicans-promoted oral epithelial dysplasia. Med Mycol (2008) 0.89
Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog (2008) 0.86
The role of the IL-12 cytokine family in directing T-cell responses in oral candidosis. Clin Dev Immunol (2010) 0.81
A novel renal epithelial cell in vitro assay to assess Candida albicans virulence. Virulence (2013) 0.80
Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. Infect Immun (2016) 0.76
Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization. Front Microbiol (2017) 0.75
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med (2002) 2.63
Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother (1992) 2.22
Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials (1999) 2.10
The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis (1996) 2.03
New model of oropharyngeal candidiasis in mice. Antimicrob Agents Chemother (2001) 1.93
Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother (1985) 1.91
Experimental oral candidiasis in animal models. Clin Microbiol Rev (2001) 1.42
Gastrointestinal candidiasis in rats treated with antibiotics, cortisone, and azathioprine. Infect Immun (1976) 1.41
Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun (1980) 1.34
Fungal infections in cancer patients: an escalating problem. In Vivo (1992) 1.28
Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother (1991) 1.23
Factors affecting colonization and dissemination of Candida albicans from the gastrointestinal tract of mice. Infect Immun (1987) 1.23
Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infect Immun (1982) 1.23
Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrob Agents Chemother (1990) 1.22
Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice. Antimicrob Agents Chemother (1990) 1.20
Ketoconazole in experimental candidosis. Rev Infect Dis (1981) 1.19
Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis. J Antimicrob Chemother (1993) 1.12
Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program (2003) 1.11
Fungal infections in iatrogenically compromised hosts. Adv Intern Med (1998) 0.97
COS-l, a putative two-component histidine kinase of Candida albicans, is an in vivo virulence factor. Med Mycol (2001) 0.97
Effects of gastrointestinal candidiasis, antibiotics, dietary arabinitol, and cortisone acetate on levels of the Candida metabolite D-arabinitol in rat serum and urine. Infect Immun (1990) 0.96
Experimental models in antifungal chemotherapy. Mycoses (1998) 0.96
Effects of broad-spectrum antibiotics on colonization of gastrointestinal tracts of mice by Candida albicans. Antimicrob Agents Chemother (1994) 0.95
New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Antimicrob Agents Chemother (1996) 0.95
Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs (2003) 0.92
Candida albicans gastrointestinal colonization and invasion in the mouse: effect of antibacterial dosing, antifungal therapy and immunosuppression. Mycoses (1989) 0.89
Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model. J Antimicrob Chemother (2002) 0.89
Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. J Antimicrob Chemother (2001) 0.89
Cecal colonization and systemic spread of Candida albicans in mice treated with antibiotics and dexamethasone. Pediatr Res (2002) 0.89
Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol (2000) 0.88
Mice with persistent gastrointestinal Candida albicans as a model for antifungal therapy. Antimicrob Agents Chemother (1982) 0.88
Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun (2004) 0.86
Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob Agents Chemother (2001) 0.86
Antibiotics affecting gastrointestinal colonization of mice by yeasts. J Chemother (1994) 0.84
Invasive candidiasis during granulocytopenia. Recent Results Cancer Res (1993) 0.83
Interaction of Candida albicans with murine gastrointestinal mucosa: effect of irradiation on adherence in vitro. J Med Vet Mycol (1989) 0.82
Fungal infections in patients with cancer. Pharmacotherapy (1990) 0.80
Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans. Antimicrob Agents Chemother (1996) 0.79
Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment. J Med Vet Mycol (1992) 0.78
Interaction of Candida albicans with murine gastrointestinal mucosa from methotrexate and 5-fluorouracil treated animals: in vitro adhesion and prevention. J Med Vet Mycol (1990) 0.78
Systemic and gastrointestinal candidiasis of infant mice as model for antifungal therapy. Indian J Exp Biol (1993) 0.77
Treatment of gastrointestinal candidosis in predisposed guinea-pigs and in conventional mice with miconazole. Mykosen (1978) 0.77
Control of systemic spread of Candida albicans with ketoconazole in the stomachs of mice treated with cytarabine. J Infect Dis (1983) 0.76
Gut colonization of mice by yeast: effects of methylprednisolone and antibiotics. Hepatogastroenterology (1998) 0.76
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Coccidioidomycosis. Clin Infect Dis (2005) 3.88
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
Caspofungin. Clin Infect Dis (2003) 3.03
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother (2004) 2.28
Coccidioidomycosis. Infect Dis Clin North Am (2003) 2.13
Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med (2008) 1.82
Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One (2013) 1.79
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother (2006) 1.76
Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology (2007) 1.73
Antifungal drug resistance. Clin Infect Dis (2003) 1.65
Comparative study of attenuation of the pain caused by propofol intravenous injection, by granisetron, magnesium sulfate and nitroglycerine. Saudi J Anaesth (2011) 1.61
Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again? J Med Microbiol (2011) 1.52
Optical properties of an immobilized DNA monolayer from 255 to 700 nm. Langmuir (2004) 1.52
Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol (2009) 1.49
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis (2003) 1.44
Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology (2002) 1.43
Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36
Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis (2003) 1.33
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2002) 1.22
Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother (2003) 1.19
Development of a murine model of cerebral aspergillosis. J Infect Dis (2002) 1.19
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol (2006) 1.06
Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia (2007) 1.05
Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother (2003) 1.02
New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol (2010) 1.02
Animal models: an important tool in mycology. Med Mycol (2007) 1.01
Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J Infect Dis (2002) 1.00
Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun (2004) 1.00
Molecular characterization and antimicrobial susceptibility of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico. J Med Microbiol (2010) 0.99
Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother (2008) 0.98
Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrob Agents Chemother (2004) 0.98
Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis (2008) 0.98
Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob Agents Chemother (2012) 0.97
Metallic taste from electrical and chemical stimulation. Chem Senses (2005) 0.97
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis (2007) 0.96
Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother (2006) 0.96
Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother (2004) 0.94
Overexpression of WsSGTL1 gene of Withania somnifera enhances salt tolerance, heat tolerance and cold acclimation ability in transgenic Arabidopsis plants. PLoS One (2013) 0.94
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med Mycol (2011) 0.92
Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother (2012) 0.92
Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis (2003) 0.91
Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother (2005) 0.90
Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J Infect Dis (2006) 0.90
Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine (2009) 0.89
Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 0.89
Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine (2011) 0.88
Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother (2007) 0.88
Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev (2011) 0.87
Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother (2003) 0.87
Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis. Infect Immun (2007) 0.87
Demonstration of a novel technique to quantitatively assess inflammatory mediators and cells in rat knee joints. J Inflamm (Lond) (2007) 0.86
Huge mesenchymal chondrosarcoma of mandible. J Maxillofac Oral Surg (2011) 0.86
A murine model of coccidioidal meningitis. J Infect Dis (2003) 0.86
Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun (2004) 0.86
Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol (2010) 0.86
Who let the dogs out? Infection control did: utility of dogs in health care settings and infection control aspects. Am J Infect Control (2006) 0.86
Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol (2012) 0.86
Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease. Mycopathologia (2014) 0.85
Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D. Infect Immun (2006) 0.85
Buccal fat pad versus sandwich graft for treatment of oroantral defects: A comparison. Natl J Maxillofac Surg (2010) 0.85
Circulation of Dengue virus-1 (DENV-1) serotype in Delhi, during 2010-11 after Dengue virus-3 (DENV-3) predominance: a single centre hospital-based study. J Vector Borne Dis (2012) 0.84
Genomic DNA microarray comparison of gene expression patterns in Paracoccidioides brasiliensis mycelia and yeasts in vitro. Microbiology (2009) 0.84
Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect (2004) 0.84
Alternatives to amphotericin B for Candida rugosa infection. J Antimicrob Chemother (2004) 0.83
Real-time PCR and quantitative culture for monitoring of experimental Aspergillus fumigatus intracranial infection in neutropenic mice. J Med Microbiol (2011) 0.83
Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. Clin Infect Dis (2011) 0.83
Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother (2005) 0.83
Saccharomyces as a vaccine against systemic candidiasis. Immunol Invest (2012) 0.82
Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med Mycol (2006) 0.82
Global population structure of Aspergillus terreus inferred by ISSR typing reveals geographical subclustering. BMC Microbiol (2011) 0.82
Influence of 17β-estradiol on gene expression of Paracoccidioides during mycelia-to-yeast transition. PLoS One (2011) 0.82
Molecular epidemiology of the global and temporal diversity of Candida parapsilosis. Scand J Infect Dis (2008) 0.81
Resistance of MBL gene-knockout mice to experimental systemic aspergillosis. Immunol Lett (2010) 0.81
Microsatellite multilocus genotyping clarifies the relationship of Candida parapsilosis strains involved in a neonatal intensive care unit outbreak. Diagn Microbiol Infect Dis (2011) 0.81
Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area. Mycopathologia (2004) 0.81
Inflammatory marker profiles in an avian experimental model of aspergillosis. Med Mycol (2013) 0.81
Experimental animal models of coccidioidomycosis. Ann N Y Acad Sci (2007) 0.81